热速清治疗小儿急性上呼吸道感染有效性和安全性的Meta分析

Meta-Analysis of the Effectiveness and Safety of Resuqing in the Treatment of Children with Acute Upper Respiratory Tract Infection

摘要: 目的：系统评价热速清治疗小儿急性上呼吸道感染的有效性。方法：检索了中国期刊全文数据库(CNKI)、万方数据库(WanFang)、中国生物医学文献数据库(CBM)、维普资讯中文科技期刊数据库(VIP)、PubMed、EMbase、Cochrane Library、Web of Science，收集热速清治疗急性上呼吸道感染的随机对照试验，检索时间为该数据库建库至2026年3月10日，采用Cochrane偏倚风险评估工具对纳入文献进行评价，应用RevMan 5.4.1软件进行Meta分析。最终纳入14项研究，总样本量例2850，试验组1777例，对照组1073例。结果：临床疗效总有效率[RR = 1.20, 95% CI (1.12, 1.28), P < 0.00001]、开始退热时间[MD = −3.71, 95% CI (−5.61, −0.72), P = 0.01]、完全退热时间[MD = −8.25, 95% CI (−12.99, −3.51), P = 0.0006]及中医证候疗效[RR = 1.22, 95% CI (0.92, 1.63), P = 0.04]。不良反应方面，纳入文献中有7项提及不良反应，3项研究明确说明无不良反应，7项研究未提及，故该研究尚不能对热速清的安全性做出肯定性评价。结论：与对症治疗相比，联合使用热速清治疗小儿上感可能更佳，但鉴于纳入文献偏倚风险较高，今后仍需更多大样本高质量的随机对照试验予以完善。

Abstract: Objective: To systematically evaluate the effectiveness of Resuqing, a traditional Chinese medicine, in treating pediatric acute upper respiratory tract infections. Methods: Randomized controlled trials (RCTs) on Resuqing for acute upper respiratory tract infection were retrieved from the China National Knowledge Infrastructure (CNKI), WanFang Database, Chinese Biomedical Literature Database (CBM), VIP Chinese Science and Technology Periodical Database, PubMed, EMbase, Cochrane Library, and Web of Science. The search period covered from the inception of each database to March 10, 2026. The Cochrane Risk of Bias Tool was used to assess the quality of the included studies, and a meta-analysis was performed using RevMan 5.4.1 software. A total of 14 studies were ultimately included, with a total sample size of 2,850 cases (1,777 in the experimental group and 1,073 in the control group). Results: The overall clinical response rate was [RR = 1.20, 95% CI (1.12, 1.28), P < 0.00001], the time to initial fever resolution was [MD = −3.71 hours, 95% CI (−5.61, −0.72), P = 0.01], the time to complete fever resolution was [MD = −8.25 hours, 95% CI (−12.99, −3.51), P = 0.0006], and the efficacy regarding TCM syndromes was [RR = 1.22, 95% CI (0.92, 1.63), P = 0.04]. Safety evaluation revealed limited data: 7 studies mentioned adverse reactions (3 explicitly reported none), while 7 omitted safety details, precluding definitive conclusions on Resuqing’s safety. Conclusion: Compared with symptomatic treatment alone, the combined use of Resuqing may offer better therapeutic effects for acute upper respiratory tract infection in children. However, given the high risk of bias in the included studies, further large-sample, high-quality randomized controlled trials are needed to confirm these findings.